Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $188 | $368 | $977 | $5,544 |
| - Cash | $36 | $42 | $61 | $134 |
| + Debt | $85 | $104 | $109 | $115 |
| Enterprise Value | $237 | $430 | $1,025 | $5,525 |
| Revenue | $14 | $64 | $96 | $56 |
| % Growth | -78.5% | -34% | 72.4% | – |
| Gross Profit | $14 | -$94 | $83 | $50 |
| % Margin | 100% | -147.4% | 85.7% | 89.5% |
| EBITDA | -$177 | -$172 | -$295 | -$211 |
| % Margin | -1,295.4% | -271.1% | -305.9% | -378.1% |
| Net Income | -$186 | -$161 | -$282 | -$212 |
| % Margin | -1,366.5% | -253.3% | -292.5% | -379.9% |
| EPS Diluted | -1.64 | -1.64 | -2.91 | -2.24 |
| % Growth | 0% | 43.6% | -29.9% | – |
| Operating Cash Flow | -$123 | -$132 | -$248 | -$163 |
| Capital Expenditures | -$1 | -$6 | -$36 | -$51 |
| Free Cash Flow | -$124 | -$138 | -$284 | -$214 |